Sign in
Taking people in United StatesPhase 2

Tests enfortumab vedotin and pembrolizumab, then pembrolizumab maintenance, for bladder cancer

Tests two drugs followed by maintenance therapy in adults with advanced urothelial carcinoma.

Key facts

Who runs it
Fox Chase Cancer Center
Where
Philadelphia, United StatesSee the site
Trial code
Registry title
Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma
Status
Recruiting
Phase
Phase 2
People taking part
97 people, planned
Started
23 Jan 2026
Expected to end
3 Sept 2029
Type of study
Interventional
Treatments tested
  • Enfortumab vedotin
  • Pembrolizumab
Record updated
19 February 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with urothelial (bladder or urinary tract) cancer that has spread or cannot be removed by surgery, and who have not had drug treatment for it yet.

Age
18 years or older
Sex
Women and men can join.
Disease stage
Urothelial carcinoma, confirmed by tissue test and scans, that is locally advanced and cannot be removed by surgery, or has spread. At least one tumour that can be measured on scans.
Earlier treatment
No earlier drug treatment for spread disease. Earlier immunotherapy before or after surgery is allowed if it ended at least 12 months before. Earlier MMAE-based antibody-drug conjugates for urothelial cancer are not allowed.

Main reasons for not taking part

  • Earlier MMAE-based antibody-drug conjugate for urothelial cancer
  • Nerve damage (neuropathy) of grade 2 or higher
  • Uncontrolled diabetes (HbA1c above 8% (64 mmol/mol))
  • Untreated or uncontrolled brain or spinal cord metastases
  • Known HIV on antiretroviral therapy, earlier organ or stem cell transplant, or active autoimmune disease treated in the past 2 years

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • Patients must have histologically and radiographically confirmed locally advanced, unresectable urothelial carcinoma
  • Patients should not have received prior systemic therapy for metastatic disease
  • Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with RECIST criteria v1.1
  • Patients may have received prior neoadjuvant or adjuvant immune checkpoint inhibitor therapy for localized disease and are eligible if they completed the treatment ≥12 months prior to initiating treatment on this clinical trial
  • ECOG performance status 0-2
  • Ability to understand and willingness to sign a written informed consent and HIPAA consent document
  • Archival tumor biospecimen (when available) must be procured for correlative evaluation. If tumor tissue is not available or accessible despite good faith efforts, patient may still be treated on study. Formalin fixed, paraffin embedded (FFPE) tissue block(s) or at least 25 unbaked, unstained slides are required. Tissue samples taken from a metastatic lesion prior to the start of screening are acceptable
  • Normal organ and marrow function as defined below; Absolute neutrophil count > 1,000/mm3 unless patient has constitutional neutropenia; Platelets > 100,000/µl; Hemoglobin > 8.0 g/dL; Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <2.5 x upper limit of normal (ULN) or <3.5 x ULN if liver metastases; Creatinine Clearance >20 ml/min

Who cannot take part

  • Patients who have received prior monomethyl auristatin E (MMAE)-based antibody-drug conjugates (ADCs) for urothelial cancer
  • Patients with uncontrolled and untreated central nervous system (CNS) metastases; Prior radiation to CNS metastases is permitted; Prior history of CNS disease that has responded to previous systemic therapy is permitted only if no recurrence; Patient should not have leptomeningeal disease; CNS metastases have been clinically stable for at least 6 weeks prior to screening and baseline scans show no evidence of new or enlarged metastasis; If requiring steroid treatment for CNS metastases, the patient is on stable dose < 10 mg/day of prednisone or equivalent for at least 2 weeks prior to starting treatment
  • Currently receiving systemic antimicrobial treatment for active infection (viral, bacterial, or fungal) at the time of first dose of enfortumab vedotin. Routine antimicrobial prophylaxis is permitted
  • Prior allogeneic stem cell or solid organ transplant
  • Patients who received prior immunotherapy for mUC or for an alternative malignancy are eligible unless they developed an immune related adverse event while on therapy requiring cessation of therapy or use of disease modifying agents, corticosteroids, or immunosuppressive drugs
  • Uncontrolled intercurrent illness including, but not limited to ongoing or active untreated infection, symptomatic congestive heart failure, unstable angina pectoris, symptomatic uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that, in the opinion of the investigator, would substantially impair the patient's ability to comply with study requirements. Efforts should be made to provide reasonable accommodations before determining exclusion based on social limitations
  • Subjects with a history of another invasive malignancy within 3 years before the first dose of study drug that cannot be watched and requires treatment, or any evidence of residual disease from a previously diagnosed malignancy that cannot be watched and requires treatment. Adjuvant hormonal therapy for breast cancer is allowed
  • Known HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with enfortumab vedotin
  • History of idiopathic pulmonary fibrosis; organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan
  • Other underlying medical condition that, in the opinion of the investigator, would impair the ability of the patient to receive or tolerate the planned treatment and follow-up; any known psychiatric or substance abuse disorders that would interfere with cooperating with the requirements of the study
  • Patients with active tuberculosis
  • History of autoimmune diseases. Has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., use of disease modifying agents, corticosteroids, or immunosuppressive drugs); Patients with vitiligo or residual autoimmune hypothyroidism on stable doses of hormone replacement are permitted to enroll; Patients with type 1 diabetes mellitus (T1DM) on a stable dose of insulin are permitted to enroll; Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed
  • On high dose steroids at the time of study enrollment, defined as >10 mg prednisone (or bioequivalent), including steroids used for management of intracranial lesions. Inhaled or topical steroids are permitted in the absence of active autoimmune disease
  • Uncontrolled diabetes (HbA1c >8%)
  • Grade 2 or higher baseline sensory or motor neuropathy
  • Pregnant or breast feeding

Where in United States

  • Fox Chase Cancer Center - PhiladelphiaPhiladelphia, United StatesContact: Pooja Ghatalia, MDTaking people

About the trial

What the trial wants to find out

This is a single-arm, open-label, non-randomized Phase II trial evaluating the efficacy of induction therapy with enfortumab vedotin (EV) plus pembrolizumab (P) for 18 weeks (6 cycles), followed by maintenance pembrolizumab in treatment-naïve patients with metastatic urothelial carcinoma (mUC). Approximately 97 patients will be enrolled. Induction consists of EV (1.25 mg/kg IV on Days 1 and 8 of each 21-day cycle; starting dose of 1 mg/kg allowed) and P (200 mg IV on Day 1 of each cycle). Radiographic assessments occur after 3 and 6 cycles. Patients achieving complete or partial response transition to maintenance P (400 mg IV every 6 weeks or 200 mg IV every 3 weeks) for up to 2 years. Dose modifications for EV are permitted per protocol; no dose adjustments for P. Treatment continues until disease progression, unacceptable toxicity, or completion of maintenance therapy. Patients will enter long-term or survival follow-up as applicable.

The group in the trial

  • Induction EV + Pembrolizumab Followed by Maintenance PembrolizumabTreatment being tested

    Participants will receive induction therapy with enfortumab vedotin (EV) plus pembrolizumab (P) for 6 cycles (approximately 18 weeks). EV will be administered at 1.25 mg/kg IV on Days 1 and 8 of each 21-day cycle (starting dose of 1 mg/kg allowed), and pembrolizumab at 200 mg IV on Day 1 of each cycle. Patients achieving complete or partial response will transition to maintenance pembrolizumab at 400 mg IV every 6 weeks or 200 mg IV every 3 weeks for up to 2 years. Dose modifications for EV are permitted per protocol; no dose adjustments for pembrolizumab. Treatment continues until disease progression, unacceptable toxicity, or completion of maintenance therapy.

    Treatment: Enfortumab vedotin and Pembrolizumab

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Pembrolizumab Maintenance After Enfortumab Vedotin/Pembrolizumab Induction in Front-Line Metastatic Urothelial Carcinoma
Plain-language title
Tests enfortumab vedotin and pembrolizumab, then pembrolizumab maintenance, for bladder cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
19 February 2026